Inhibition of cytochrome P4502C9 activity in vitro by 5-hydroxytryptamine and adrenaline

被引:15
|
作者
Gervasini, G
Martínez, C
Agúndez, JAG
García-Gamito, FJ
Benítez, J
机构
[1] Univ Extremadura, Fac Med, Dept Farmacol, E-06071 Badajoz, Spain
[2] INSALUD Hosp Merida, Serv Gen Surg, Badajoz, Spain
来源
PHARMACOGENETICS | 2001年 / 11卷 / 01期
关键词
diclofenac; CYP2C9; microsomes;
D O I
10.1097/00008571-200102000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the present study, the occurrence of a modulatory effect of 14 neurotransmitters, precursors and metabolites on the cytochrome P450 2C9 (CYP2C9) enzyme activity, as determined by diclofenac 4-hydroxylation, was studied in human liver microsomes. Two indoleamines, 5-hydroxytryptamine (5-HT) and adrenaline, showed a non-competitive-type inhibitory effect of approximately 90% of the diclofenac 4-hydroxylase activity, with K-i values of 63.5 (0.7 and 156 (89.3 muM, respectively. The rest of substances analysed were weak inhibitors or had no inhibitory effect, CYP2C subfamily is present in human brain, although CYP2C9 isozyme has not yet been identified in this tissue, and CYP2C9 is involved in the metabolism of psychoactive drugs. Therefore, the fact that endogenous compounds could modulate the CYP2C9 activity, suggests that an hypothetical local activity of brain CYP2C9 might be susceptible to regulatory mechanisms. The possible clinical implications of this modulation are discussed. Pharmacogenetics 11:29-37 (C) Lippincott Williams & Wilkins.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 50 条
  • [31] Cytochrome P4502C9 Activity Is Unaffected by Oral Contraceptive Use Among Obese Women
    Cherala, Ganesh
    Edelman, Alison
    JOURNAL OF WOMENS HEALTH, 2013, 22 (10) : 885 - 886
  • [32] Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes
    Lee, CR
    Pieper, JA
    Hinderliter, AL
    Blaisdell, JA
    Goldstein, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) : 562 - 571
  • [33] Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolisers
    Verstuyft, C
    Morin, S
    Robert, A
    Loriot, MA
    Beaune, P
    Jaillon, P
    Becquemont, L
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R113 - R113
  • [34] Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolizers
    Verstuyft, C
    Morin, S
    Robert, A
    Loriot, MA
    Beaune, P
    Jaillon, P
    Becquemont, L
    PHARMACOGENETICS, 2001, 11 (08): : 735 - 737
  • [35] Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners, JO
    Birkett, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 525 - 538
  • [36] Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population
    Scordo, MG
    Aklillu, E
    Yasar, U
    Dahl, ML
    Spina, E
    Ingelman-Sundberg, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 447 - 450
  • [37] Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9
    Jones, JP
    He, MX
    Trager, WF
    Rettie, AE
    DRUG METABOLISM AND DISPOSITION, 1996, 24 (01) : 1 - 6
  • [38] Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo
    Tassaneeyakul, W
    Birkett, DJ
    Pass, MC
    Miners, JO
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) : 774 - 778
  • [39] Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Demmark
    Pedersen, RS
    Verstuyft, C
    Becquemont, L
    Jaillon, P
    Brosen, K
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 94 (03) : 151 - 152
  • [40] Frequency of cytochrome P4502C9 allelic variants in the Chinese and French populations
    Yang, JQ
    Morin, S
    Verstuyft, C
    Fan, LA
    Zhang, Y
    Di Xu, C
    Barbu, V
    Jaillon, P
    Becquemont, L
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (03) : 373 - 376